Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2020
Reporting Period: Specific event date of January 28, 2020.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow from operations).
- Capital Raised: $2.0 million
- Shares Issued: 1,250,000 shares of Class A common stock
- Price Per Share: $1.60
- Investor: MacAndrews & Forbes Group LLC
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity positions as of this date.
Material Changes
The material change reported is the unregistered sale of equity securities pursuant to a letter agreement dated December 23, 2019. On January 28, 2020, the Company exercised its right to require the Investor to purchase the shares, resulting in the immediate infusion of $2.0 million in cash.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of definitive documentation and the funding of the transaction. It references the December 2019 Letter Agreement for full terms, noting that the agreement will be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2019.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard disclosure of the equity sale. The transaction was conducted under the terms of a pre-existing agreement.
Investor Verification Checklist
- Verify the full terms of the December 23, 2019 Letter Agreement in the upcoming Form 10-K exhibit.
- Confirm the impact of the $2.0 million cash infusion on the company's liquidity and runway.
- Review the dilution impact of the 1,250,000 newly issued shares on existing shareholders.
- Check for any subsequent filings regarding the use of proceeds from this capital raise.